ANI Pharmaceuticals Non-GAAP EPS of $2.05 beats by $0.75, revenue of $237.5M beats by $29.87M
Source: SeekingAlpha
2026-05-08 06:54:30 ET
More on ANI Pharmaceuticals
- ANI Pharmaceuticals Looks Undervalued As Cortrophin Drives Rare Disease Growth
- ANI Pharmaceuticals: Worthy Of A Position
- ANI Pharmaceuticals, Inc. (ANIP) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
- ANI Pharmaceuticals Q1 2026 Earnings Preview
- ANI Pharmaceuticals targets over $1B in 2026 revenue with rare disease focus and expanded sales force
Read the full article on Seeking Alpha
For further details see:
ANI Pharmaceuticals Non-GAAP EPS of $2.05 beats by $0.75, revenue of $237.5M beats by $29.87M
ANI Pharmaceuticals Inc.
NASDAQ: ANIP
ANIP Trading
1.77% G/L:
$80.49 Last:
86,712 Volume:
$79.77 Open:
ANIP Latest News
May 27, 2026 06:50:00 am
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
May 11, 2026 05:29:29 pm
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million
May 08, 2026 06:50:00 am
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
ANIP Stock Data
$1,800,695,910
19,965,311
5.78%
107
N/A
Pharmaceuticals
Healthcare
US
Baudette
